佳妹儿
Lv2
200 积分
2024-03-06 加入
-
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
5天前
已完结
-
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
11天前
已完结
-
Current developments in gastric cancer: from molecular profiling to treatment strategy
13天前
已完结
-
Peritoneal carcinomatosis of gastric origin: A population‐based study on incidence, survival and risk factors
13天前
已完结
-
Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value
13天前
已完结
-
胆管癌免疫治疗的研究进展
13天前
已完结
-
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
18天前
已完结
-
Co-occurring EGFR p.E709X mutation Mediates Primary Resistance to the Third-generation EGFR-TKIs in EGFR p.G719X-mutant Patients with Advanced NSCLC
18天前
已完结
-
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
18天前
已完结
-
Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial
18天前
已完结